| scholarly article | Q13442814 |
| P2093 | author name string | Haishan Li | |
| C David Pauza | |||
| Rena G Lapidus | |||
| Tyler Lahusen | |||
| Cristiana Cairo | |||
| Mei-Ling Liou | |||
| Lingzhi Xiao | |||
| P2860 | cites work | Immunohistochemical study of tumor-infiltrating lymphocytes before and after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer | Q73406294 |
| CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes | Q74460215 | ||
| Anti-myeloma activity of pamidronate in vivo | Q77597686 | ||
| Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma | Q81562346 | ||
| Characterization of the gammadelta T cell response to acute leukemia | Q81575021 | ||
| Differential production of gamma delta T cells in the urine of bladder cancer patients receiving Bacillus Calmette Guerin immunotherapy | Q84009463 | ||
| The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation | Q84473603 | ||
| Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells | Q24316370 | ||
| Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset | Q24339540 | ||
| IL-17A-producing CD30(+) Vδ1 T cells drive inflammation-induced cancer progression | Q26744206 | ||
| What lessons can be learned from γδ T cell-based cancer immunotherapy trials? | Q26849323 | ||
| γδ T cells for cancer immunotherapy: A systematic review of clinical trials | Q27021705 | ||
| The Molecular Basis for Modulation of Human V 9V 2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies | Q27670973 | ||
| γδ T cells in cancer immunotherapy | Q28068988 | ||
| γδ T Cells in HIV Disease: Past, Present, and Future | Q28084822 | ||
| Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells | Q28215003 | ||
| Nonpeptide ligands for human gamma delta T cells | Q28369364 | ||
| Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer | Q28659468 | ||
| IMGT/3Dstructure-DB and IMGT/StructuralQuery, a database and a tool for immunoglobulin, T cell receptor and MHC structural data | Q30886362 | ||
| STAT3 regulates cytotoxicity of human CD57+ CD4+ T cells in blood and lymphoid follicles | Q50348783 | ||
| Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma | Q51045550 | ||
| Butyrophilin3A proteins and Vγ9Vδ2 T cell activation. | Q54268399 | ||
| γδ T Cells: Unexpected Regulators of Cancer Development and Progression | Q54326921 | ||
| Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. | Q54367882 | ||
| IMGT, the international ImMunoGeneTics database | Q57339967 | ||
| Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma | Q57949352 | ||
| Chronic In Vivo Interaction of Dendritic Cells Expressing the Ligand Rae-1ε with NK Cells Impacts NKG2D Expression and Function | Q58620998 | ||
| Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency | Q67904380 | ||
| Stimulation of a major subset of lymphocytes expressing T cell receptor gamma delta by an antigen derived from Mycobacterium tuberculosis | Q69301335 | ||
| Human V gamma 9-V delta 2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites | Q71918639 | ||
| Human peripheral gamma delta T cells are stimulated by Daudi Burkitt's lymphoma and not by any other Burkitt's lymphoma tested | Q72496749 | ||
| Pharmacokinetics of alendronate: an overview | Q73202765 | ||
| Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update | Q47275046 | ||
| Intratumoral immunotherapy: using the tumor as the remedy | Q47281370 | ||
| FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. | Q47391978 | ||
| Gamma-delta (γδ) T cells: friend or foe in cancer development? | Q47742552 | ||
| IL-33-expanded human Vγ9Vδ2 T cells have anti-lymphoma effect in a mouse tumor model | Q48031093 | ||
| Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing γδ T cell biology | Q48232215 | ||
| BCG immunotherapy of bladder cancer: 20 years on. | Q33640029 | ||
| Implication of gammadelta T cells in the human immune response to cytomegalovirus | Q33854964 | ||
| Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. | Q33905819 | ||
| Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug | Q33920919 | ||
| Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. | Q33965681 | ||
| Identification of (E)‐4‐hydroxy‐3‐methyl‐but‐2‐enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli | Q34104852 | ||
| Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens | Q34170227 | ||
| Mechanisms underlying γδ T-cell subset perturbations in SIV-infected Asian rhesus macaques | Q34360320 | ||
| Full Restoration of Brucella-Infected Dendritic Cell Functionality through Vγ9Vδ2 T Helper Type 1 Crosstalk | Q34395849 | ||
| Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies | Q34517192 | ||
| Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis | Q34580943 | ||
| Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro | Q34802235 | ||
| Cancer Incidence in HIV-Infected Versus Uninfected Veterans: Comparison of Cancer Registry and ICD-9 Code Diagnoses | Q34849149 | ||
| Gamma interferon secretion by human Vgamma2Vdelta2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-Like receptor 2 agonist Pam3Cys | Q34975891 | ||
| Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood | Q34983193 | ||
| Sensing of Pyrophosphate Metabolites by Vγ9Vδ2 T Cells. | Q35000371 | ||
| Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma | Q35226178 | ||
| The antituberculous Mycobacterium bovis BCG vaccine is an attenuated mycobacterial producer of phosphorylated nonpeptidic antigens for human gamma delta T cells | Q35454235 | ||
| Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells | Q35458425 | ||
| Ex vivo expanded human circulating Vδ1 γδT cells exhibit favorable therapeutic potential for colon cancer | Q35506504 | ||
| Evolution and function of the TCR Vgamma9 chain repertoire: It's good to be public | Q35739148 | ||
| Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma | Q35847391 | ||
| Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement | Q35883004 | ||
| Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin | Q36366439 | ||
| Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells | Q36402321 | ||
| Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells | Q36403003 | ||
| γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. | Q36473289 | ||
| Effector and regulatory events during natural killer-dendritic cell interactions | Q36652210 | ||
| Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human Vγ2Vδ2 T Cells | Q36845046 | ||
| Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors. | Q37079078 | ||
| T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. | Q37390723 | ||
| Intraepithelial gammadelta T cells may bridge a gap between innate immunity and acquired immunity to herpes simplex virus type 2 | Q37423165 | ||
| Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals | Q37515155 | ||
| Human γδT-cell subsets and their involvement in tumor immunity. | Q37714642 | ||
| Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity | Q37764294 | ||
| Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy | Q37799384 | ||
| Recognition of mycobacterial antigens by gamma delta T cells | Q37868051 | ||
| Cross-Talks between Natural Killer Cells and Distinct Subsets of Dendritic Cells | Q38208307 | ||
| Dendritic cell editing by natural killer cells | Q38221226 | ||
| Human gamma delta T regulatory cells in cancer: fact or fiction? | Q38283534 | ||
| The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy | Q38347451 | ||
| γδ T cell therapy for the treatment of non-small cell lung cancer. | Q38390100 | ||
| CD57 in human natural killer cells and T-lymphocytes | Q38724544 | ||
| Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis | Q38739527 | ||
| Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment | Q38779257 | ||
| Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer | Q38787725 | ||
| Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells. | Q38866959 | ||
| Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid | Q38945626 | ||
| Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes | Q38985338 | ||
| Repeated Systemic Administrations of Both Aminobisphosphonates and Human Vγ9Vδ2 T Cells Efficiently Control Tumor Development In Vivo | Q39128768 | ||
| Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens | Q39602547 | ||
| Analysis of tumor-infiltrating gamma delta T cells in rectal cancer | Q39704837 | ||
| Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells | Q39842998 | ||
| IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. | Q39876506 | ||
| BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain | Q40070853 | ||
| Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation | Q40093467 | ||
| Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model | Q40146526 | ||
| Skewed T cell receptor repertoire of Vdelta1(+) gammadelta T lymphocytes after human allogeneic haematopoietic stem cell transplantation and the potential role for Epstein-Barr virus-infected B cells in clonal restriction | Q40147291 | ||
| Interleukin-18 activates Vγ9Vδ2+ T cells from HIV-positive individuals: recovering the response to phosphoantigen. | Q40274003 | ||
| Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab | Q40355238 | ||
| Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. | Q40457697 | ||
| Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study | Q40613562 | ||
| Uncoupling between Immunological Synapse Formation and Functional Outcome in Human γδ T Lymphocytes | Q40618363 | ||
| Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates | Q40783969 | ||
| gamma delta T-cell-human glial cell interactions. I. In vitro induction of gammadelta T-cell expansion by human glial cells | Q41119050 | ||
| Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice | Q41312059 | ||
| Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts | Q41600980 | ||
| A large fraction of human peripheral blood gamma/delta + T cells is activated by Mycobacterium tuberculosis but not by its 65-kD heat shock protein | Q41841463 | ||
| Vγ2Vδ2 T cell Costimulation Increases NK cell Killing of Monocyte-derived Dendritic Cells | Q42187331 | ||
| Vγ9 and Vδ2 T cell antigen receptor genes and butyrophilin 3 (BTN3) emerged with placental mammals and are concomitantly preserved in selected species like alpaca (Vicugna pacos). | Q42237075 | ||
| In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients | Q43057295 | ||
| Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells | Q44043116 | ||
| Gammadelta T cells for immune therapy of patients with lymphoid malignancies | Q44353687 | ||
| Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin. | Q45968483 | ||
| Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. | Q46036025 | ||
| Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation | Q46902168 | ||
| Current Advances in γδ T Cell-Based Tumor Immunotherapy | Q47100174 | ||
| Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer | Q47134013 | ||
| Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice | Q47257398 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 1305 | |
| P577 | publication date | 2018-06-08 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local | |
| P478 | volume | 9 |
| Q91855561 | Challenges in assessing solid tumor responses to immunotherapy |
| Q90681174 | Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors |
| Q96303605 | Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing Vγ9Vδ2 T Cells |
| Q90220072 | Heterogeneity of Human γδ T Cells and Their Role in Cancer Immunity |
| Q61445430 | Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15 |
| Q98906910 | Human immunology and immunotherapy: main achievements and challenges |
| Q96131671 | Landscape of immune cell gene expression is unique in predominantly WHO grade 1 skull base meningiomas when compared to convexity |
| Q62271302 | Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer |
| Q60937354 | Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy |
| Q89621164 | Systemic β-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of Vγ9Vδ2 T-Cells |
| Q64063170 | The Pivotal Role of Regulatory T Cells in the Regulation of Innate Immune Cells |
| Q92000263 | Vitamin C supports conversion of human γδ T cells into FOXP3-expressing regulatory cells by epigenetic regulation |
| Q90783584 | γδ T cells in cancer: a small population of lymphocytes with big implications |
| Q92929734 | γδT Cells in Lung Cancer Malignant Pleural Effusion: Friend? Foe? |
Search more.